Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recurrent coccidioidal tenosynovitis of both wrists presenting solitary soft-tissue tumors in Taiwan.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi·2026
Same author

Viral rebound and clinical outcomes in hospitalized patients with COVID-19.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Sexually transmitted enteric infections among men who have sex with men in southern Taiwan: A molecular surveillance study.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Etiological identification of Orientia tsutsugamushi by metagenomic next-generation sequencing in an adult with septic shock in Taiwan.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi·2026
Same author

Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan.

The Journal of antimicrobial chemotherapy·2026
Same author

Ceftazidime-avibactam resistance among clinical isolates of Citrobacter freundii, Morganella morganii, Providencia spp. and Serratia marcescens across five continents: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016-2023.

International journal of antimicrobial agents·2025
Same journal

Filovirus Surveillance in Communities Bordering Equatorial Guinea, Marburg Outbreak, Cameroon, 2023.

Emerging infectious diseases·2026
Same journal

Novel Parvovirus in Pigs Associated with Exophthalmos and Erythema, the Netherlands.

Emerging infectious diseases·2026
Same journal

Detection of and Early Genomic Insights into Chikungunya Virus, Bolivia, 2025.

Emerging infectious diseases·2026
Same journal

Household Transmission of Enterovirus D68, Washington and Oregon, United States, 2022-2024.

Emerging infectious diseases·2026
Same journal

New World Ocular Dirofilariasis Caused by Dirofilaria repens Infection, United States.

Emerging infectious diseases·2026
Same journal

Angiostrongylus cantonensis Rat Lungworm Detected in Rats, Madagascar, 2022-2023.

Emerging infectious diseases·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Clostridium difficile bacteremia, Taiwan.

Nan-Yao Lee1, Yu-Tsung Huang, Po-Ren Hsueh

  • 1National Cheng Kung University Hospital and Medical College, Tainan, Taiwan.

Emerging Infectious Diseases
|August 4, 2010
PubMed
Summary
This summary is machine-generated.

Clostridium difficile bacteremia (CDB) is uncommon but serious. Prompt treatment with metronidazole or vancomycin significantly improves survival rates in patients with this severe bloodstream infection.

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Related Experiment Videos

Last Updated: Jun 10, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Clinical Medicine

Background:

  • Clostridium difficile bacteremia (CDB) is an uncommon but severe complication of Clostridium difficile infection.
  • Patients with CDB often have underlying systemic diseases and gastrointestinal conditions.
  • Recent antimicrobial drug exposure is not always reported in CDB cases.

Purpose of the Study:

  • To investigate the clinical characteristics and outcomes of patients diagnosed with Clostridium difficile bacteremia.
  • To evaluate the effectiveness of different antimicrobial treatments for CDB.

Main Methods:

  • Retrospective analysis of 12 patients with CDB across two medical centers in Taiwan.
  • Clinical data collection including patient history, underlying conditions, and treatments received.
  • Antimicrobial susceptibility testing and toxin analysis of Clostridium difficile isolates.

Main Results:

  • All 12 patients had underlying systemic diseases; 5 had gastrointestinal issues, including pseudomembranous colitis.
  • Only 5 patients reported recent antimicrobial drug exposure.
  • Ten isolates were susceptible to metronidazole and vancomycin; 5 produced C. difficile toxins A or B.
  • Mortality rate was 41.7% (5/12), with 3 deaths directly attributed to CDB.
  • Patients treated with metronidazole or vancomycin had a significantly lower mortality rate (1/8) compared to those on other drugs (4/4) (p = 0.01).

Conclusions:

  • Clostridium difficile bacteremia, though infrequent, is associated with significant morbidity and mortality.
  • Metronidazole and vancomycin appear to be effective treatments for CDB.
  • Early and appropriate antimicrobial therapy is crucial for improving outcomes in patients with Clostridium difficile bacteremia.